DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

20 Biopharma Reports

Colorectal Cancer

Biomarkers in Oncology | Access &... Biomarkers in Oncology | Access & Reimbursement | Detailed, Expanded Analysis: Biomarker-Targeted Therapies for NSCLC, Malignant Melanoma, and Colorectal Cancer (US)

November 2018

Market Outlook Biomarker-driven prescribing continues to play an...

Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-......

Colorectal Cancer | Landscape &... Colorectal Cancer | Landscape & Forecast | Disease Landscape & Forecast

November 2018

Colorectal cancer is the third-most-common cancer globally and is associated...

Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by ch...

Colorectal Cancer | Current... Colorectal Cancer | Current Treatment | Detailed, Expanded Analysis (US)

August 2018

The treatment landscape for colorectal cancer is based on chemotherapies and...

The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setti......

Colorectal Cancer | Unmet Need |... Colorectal Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU)

May 2018

Market Outlook The treatment paradigm for second- and subsequent-line...

Market Outlook The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix...

Colorectal Cancer | Epidemiology |... Colorectal Cancer | Epidemiology | Mature Markets Data

January 2018

DRG Epidemiology's coverage of colorectal cancer comprises epidemiological...

DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of c......

Colorectal Cancer | Access &... Colorectal Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU5)

December 2017

Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA),...

Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)&m...

Colorectal Cancer | Epidemiology |... Colorectal Cancer | Epidemiology | Americas Data

November 2017

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...

Colorectal Cancer | Epidemiology |... Colorectal Cancer | Epidemiology | Europe Data

November 2017

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...

Colorectal Cancer | Epidemiology |... Colorectal Cancer | Epidemiology | Emerging Markets Data

November 2017

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...

Colorectal Cancer | Epidemiology |... Colorectal Cancer | Epidemiology | Middle East & Africa Data

November 2017

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...

Colorectal Cancer | Epidemiology |... Colorectal Cancer | Epidemiology | Asia Pacific Data

November 2017

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...

Colorectal Cancer | Access &... Colorectal Cancer | Access & Reimbursement | Detailed, Expanded Analysis (Brazil/Mexico)

September 2016

Introduction Colorectal cancer (CRC) affects several thousands of people in...

Introduction Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are prem...

Colorectal Cancer | Access &... Colorectal Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

July 2016

Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga...

Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the...

Colorectal Cancer | Disease... Colorectal Cancer | Disease Landscape and Forecast | G7 | 2016

July 2016

Colorectal cancer is the third-most-common cancer globally and is associated...

Colorectal cancer is the third-most-common cancer globally and is associated with a five-year OS of Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in combi......

Colorectal Cancer | Unmet Need |... Colorectal Cancer | Unmet Need | Detailed, Expanded Analysis: Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer

May 2016

Several therapies are available for treatment of second- and subsequent-line...

Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able......

The Battle Between Angiogenesis and... The Battle Between Angiogenesis and EGFR Inhibitors in Colorectal Cancer | Physician & Payer Forum | EU5 | 2015

October 2015

How Will Physician and Payer Attitudes and Decisions Shape this Market? The...

How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational sta......

Colorectal Cancer (Third-Line... Colorectal Cancer (Third-Line Advanced/Metastatic) | Decision Base | US | 2015

April 2015

How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in...

How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market? Patients with advanced/metastatic colorectal cancer (mCRC) typically r......

The Impact of Biosimilars in NHL,... The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015

March 2015

Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal...

Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (......

Colorectal Cancer | Pharmacor | G7... Colorectal Cancer | Pharmacor | G7 | 2014

August 2014

Treatment of colorectal cancer (CRC) represents a multibillion-dollar market....

Treatment of colorectal cancer (CRC) represents a multibillion-dollar market. CRC is one of the most common forms of cancer in both men and women. Over the next ten years, the number of incident ca......

Managed Care Strategies in Oncology... Managed Care Strategies in Oncology: US Payer and Prescriber Insights on the Impact of Clinical Pathways, Bundled Payments, and ACOs on Brand Uptake in Colorectal Cancer and Renal Cell Carcinoma | Physician & Payer Forum | US | 2014

February 2014

Oncology prescribing has changed with the broad adoption of clinical pathways...

Oncology prescribing has changed with the broad adoption of clinical pathways programs, bundled payment arrangements, and accountable care organizations (ACOs). Each of these managed care reforms i......

Connect